Mission Therapeutics has attracted one of the highest profile syndicates of investors in Europe. The Company has to date received £73 million in venture capital from a blue chip syndicate of institutional and corporate investors.
History of Investment
2011: Series A funding £6 million was led by Sofinnova Partners, together with Touchstone Innovations (now IP Group), SR One and the Roche Venture Fund.
2013: Series B £20 million equity financing with follow-on investment from all the existing shareholders plus a new investor, Pfizer Venture Investments.
2016: Series C £35 million funding round led by Touchstone Innovations (now IP Group) and new investor Woodford Patient Capital Trust (now Schroder Adveq) with follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments.
2020: Series C-1 £12 million funding round led by Pfizer Venture Investments with follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund, IP Group and Schroder Adveq.
Get in touch
The Glenn Berge Building
Babraham Research Campus